Qiagen
| Company type | Public company (Naamloze Vennootschap) |
|---|---|
| Industry | Biotechnology |
| Founded | 1984 |
Key people |
|
| Revenue | US$1.965 billion[1] |
Number of employees | 5,967[1] |
| Website | www.qiagen.com |
QIAGEN N.V. is a publicly traded provider of sample preparation and testing technologies for molecular diagnostics, academic research, pharmaceutical development, and applied testing. The group’s global headquarters is in Venlo, Netherlands. Regional headquarters are located in Hilden near Düsseldorf (Germany), Germantown, Maryland (USA), Shanghai (China), and Singapore.[2]
History
The company was founded on 29 November 1984 at the University of Düsseldorf as Diagen Institut für Molekulare Diagnostik by Metin Colpan, Karsten Henco, Detlev Riesner, and Jürgen Schumacher. Its first major innovation was rapid nucleic-acid purification—reducing plasmid prep time from days to hours.
Early venture capital came from TVM (Techno Venture Management). In 1996, QIAGEN went public on NASDAQ—the first German company to do so—and formed its Dutch holding, QIAGEN N.V., in Venlo. It also listed on the Frankfurt Stock Exchange that year.[3]
By 2006, revenue reached US$466 million, and headcount exceeded 1,800.[4] In June 2007, QIAGEN acquired Digene Corp. for US$1.6 billion, establishing itself in molecular diagnostics.[5]
Subsequent strategic acquisitions included DxS Ltd. (2009) for companion diagnostics, Cellestis (2011) for latent tuberculosis testing,[6] and software firms Ingenuity Systems and CLC bio in 2013 to expand into bioinformatics.[7]
In late 2011, QIAGEN announced a restructuring to cut 300–380 of its 3,800 global positions.[8] By end 2021, the workforce reached 6,000.[9]
In early 2015, QIAGEN acquired the Enzyme Solutions business from Enzymatics to support its next-generation sequencing workflow strategy.[10] In November 2015, it launched the GeneReader NGS System, the first fully integrated sample-to-report sequencing solution.[11]
In January 2018, QIAGEN moved its US listing from NASDAQ to the NYSE.[12] In April 2018, it acquired STAT-Dx and introduced QIAstat-Dx;[13] in September 2018 it joined the MDAX.[14]
In March 2020, Thermo Fisher Scientific launched a takeover bid for QIAGEN. Initial offers of €39 and later €43 per share failed when only 47 % of shares were tendered by the August 2020 deadline; QIAGEN paid a US$95 million breakup fee.[15]
During the COVID-19 pandemic, QIAGEN collaborated with governments and health agencies worldwide, offering a comprehensive portfolio of SARS-CoV-2 tests, from manual to high-throughput automated solutions.
In September 2021, QIAGEN joined Germany’s DAX index. In May 2022, it acquired a majority stake in enzyme supplier BLIRT S.A., strengthening its sample-preparation business. In January 2023, QIAGEN acquired Verogen for US$150 million, adding NGS forensic-and-human-ID technologies and the GEDmatch database.[16]
Products
QIAGEN’s offerings include Sample-to-Insight workflows, reagents, instruments, and bioinformatics software. The company serves molecular diagnostics, academic research, pharmaceutical development, and applied testing markets. Its portfolio spans over 500 products, and QIAGEN holds more than 1,000 patents.
Applications
Key growth areas include:
- Sample preparation technologies
- QuantiFERON franchise for latent tuberculosis
- QIAstat-Dx syndromic testing
- NeuMoDx high-throughput PCR
- QIAcuity digital PCR
QIAGEN offers around 120 molecular diagnostic tests for viruses, bacteria, parasites, and genetic markers. In forensic applications, its technologies support human identification and COVID-19 wastewater surveillance.[17]
Financial highlights
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| 1,418 | 1,502 | 1,526 | 1,870 | 2,252 | 2,142 | 1,965 | 1,978 | ||||||||
| 114.4 | 225.7 | –77.8 | 429.5 | 625.8 | 512.6 | 429.8 | 121.2 | ||||||||
| 5,039 | 5,748 | 5,236 | 5,913 | 6,147 | 6,288 | 6,115 | 5,690 | ||||||||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||
| 4,688 | 4,952 | 5,096 | 5,610 | 6,028 | 6,178 | 5,967 | 5,765 |
Stock market
QIAGEN shares trade on the New York Stock Exchange and Frankfurt (Prime Standard). The company joined the TecDAX in 2018 and moved to the expanded DAX on 20 September 2021.[19]
External links
- Official website: https://www.qiagen.com/
References
- ↑ 1.0 1.1 https://s28.q4cdn.com/125951340/files/doc_financials/2023/q4/2024-02-06-Press-release-QIAGEN_Q4-FY-2023-results_DE_FINAL.pdf, accessed 22 February 2024.
- ↑ https://s28.q4cdn.com/125951340/files/doc_downloads/resources/QIAGEN_Company-presentation.pdf, accessed 20 February 2024.
- ↑ Archived: biospektrum.de, 4/2004.
- ↑ QIAGEN historical development, accessed 22 February 2024.
- ↑ Qiagen press release, 3 June 2007.
- ↑ GlobeNewswire; PR Newswire.
- ↑ GenomeWeb; Xconomy.
- ↑ Reuters, 29 Nov 2011.
- ↑ QIAGEN press release, 29 July 2021.
- ↑ QIAGEN press release, accessed 29 Apr 2016.
- ↑ QIAGEN press release, accessed 29 Apr 2016.
- ↑ Handelsblatt, 15 Jan 2018.
- ↑ LaBiotech.eu, accessed 16 Jan 2019.
- ↑ Deutsche Börse index changes, 5 Sep 2018.
- ↑ Finanzen.net; Handelsblatt.
- ↑ QIAGEN press release, 9 Jan 2023.
- ↑ https://www.qiagen.com/us/applications/infectious-disease/coronavirus, accessed 29 Jul 2021.
- ↑ https://www.finanzen.net/bilanz_guv/qiagen, accessed 3 Oct 2024.
- ↑ Reuters; QIAGEN press release.